Skip to main content
MarketStoryBook

RemeGen Co., Ltd. in 1 story

The narratives 9995.HK currently appears in, with its side and exposure in each.

Bull side

1 story
  • China Becomes Pharma's Global R&D Engine

    9995.HK in “China Becomes Pharma's Global R&D Engine”

    FadingExposure: not rated yet

    Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

    A differentiated autoimmune and oncology pipeline provides several routes to overseas partnerships.

Bear side

0 stories

No bear-side stories for 9995.HK yet.